Literature DB >> 12540560

Use of a promoter trap system in Bacillus anthracis and Bacillus subtilis for the development of recombinant protective antigen-based vaccines.

O Gat1, I Inbar, R Aloni-Grinstein, E Zahavy, C Kronman, I Mendelson, S Cohen, B Velan, A Shafferman.   

Abstract

We have recently reported Bacillus anthracis attenuated live vaccine strains efficiently expressing recombinant protective antigen (rPA) and have shown a direct correlation between the level of rPA secreted by these cells and efficacy (S. Cohen, I. Mendelson, Z. Altboum, D. Kobiler, E. Elhanany, T. Bino, M. Leitner, I. Inbar, H. Rosenberg, Y. Gozes, R. Barak, M. Fisher, C. Kronman, B. Velan, and A. Shafferman, Infect. Immun. 68:4549-4558, 2000). To isolate more potent Bacillus promoters for a further increase in the production of rPA, we developed a promoter trap system based on various gfp reporter genes adapted for use in both Bacillus subtilis and B. anthracis backgrounds. Accordingly, a B. anthracis library of 6,000 clones harboring plasmids with chromosomal B. anthracis DNA fragments inserted upstream from gfpuv was constructed. Based on fluorescence intensity, 57 clones carrying potentially strong promoters were identified, some of which were DNA sequenced. The most potent B. anthracis promoter identified (Pntr; 271 bp) was 500 times more potent than the native pagA promoter and 70 times more potent than the alpha-amylase promoter (Pamy). This very potent promoter was tested along with the other promoters (which are three, six, and eight times more potent than Pamy) for the ability to drive expression of rPA in either B. subtilis or B. anthracis. The number of cell-associated pre-PA molecules in B. anthracis was found to correlate well with the strength of the promoter. However, there appeared to be an upper limit to the amount of mature PA secreted into the medium, which did not exceed that driven by Pamy. Furthermore, the rPA constructs fused to the very potent promoters proved to be deleterious to the bacterial hosts and consequently led to genetic instability of the PA expression plasmid. Immunization with attenuated B. anthracis expressing rPA under the control of promoters more potent than Pamy was less efficient in eliciting anti-PA antibodies than that attained with Pamy. The results are consistent with the notion that overexpression of PA leads to severe secretion stress and have practical implications for the design of second-generation rPA-based vaccines.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12540560      PMCID: PMC145393          DOI: 10.1128/IAI.71.2.801-813.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  45 in total

1.  Developmental switch of S-layer protein synthesis in Bacillus anthracis.

Authors:  Tâm Mignot; Stéphane Mesnage; Evelyne Couture-Tosi; Michèle Mock; Agnès Fouet
Journal:  Mol Microbiol       Date:  2002-03       Impact factor: 3.501

2.  Green fluorescent protein in the measurement of bacteria-host interactions.

Authors:  L E Bermudez; F J Sangari; A Parker
Journal:  Methods Enzymol       Date:  1999       Impact factor: 1.600

3.  Large-scale production of protective antigen of Bacillus anthracis in anaerobic cultures.

Authors:  M PUZISS; L C MANNING; J W LYNCH; I ABELOW; G G WRIGHT
Journal:  Appl Microbiol       Date:  1963-07

4.  Anthrax spores make an essential contribution to vaccine efficacy.

Authors:  Fabien Brossier; Martine Levy; Michèle Mock
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

5.  Quantitation of the capacity of the secretion apparatus and requirement for PrsA in growth and secretion of alpha-amylase in Bacillus subtilis.

Authors:  M Vitikainen; T Pummi; U Airaksinen; E Wahlström; H Wu; M Sarvas; V P Kontinen
Journal:  J Bacteriol       Date:  2001-03       Impact factor: 3.490

6.  The PrsA lipoprotein is essential for protein secretion in Bacillus subtilis and sets a limit for high-level secretion.

Authors:  V P Kontinen; M Sarvas
Journal:  Mol Microbiol       Date:  1993-05       Impact factor: 3.501

7.  Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity.

Authors:  P C Turnbull; S H Leppla; M G Broster; C P Quinn; J Melling
Journal:  Med Microbiol Immunol       Date:  1988       Impact factor: 3.402

8.  Contribution of individual toxin components to virulence of Bacillus anthracis.

Authors:  C Pezard; P Berche; M Mock
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

9.  Studies on transformation of Escherichia coli with plasmids.

Authors:  D Hanahan
Journal:  J Mol Biol       Date:  1983-06-05       Impact factor: 5.469

10.  Vaccination against anthrax with attenuated recombinant strains of Bacillus anthracis that produce protective antigen.

Authors:  J P Barnard; A M Friedlander
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

View more
  15 in total

1.  Genetic tool development for a new host for biotechnology, the thermotolerant bacterium Bacillus coagulans.

Authors:  Akos T Kovács; Mariska van Hartskamp; Oscar P Kuipers; Richard van Kranenburg
Journal:  Appl Environ Microbiol       Date:  2010-04-16       Impact factor: 4.792

2.  Search for Bacillus anthracis potential vaccine candidates by a functional genomic-serologic screen.

Authors:  Orit Gat; Haim Grosfeld; Naomi Ariel; Itzhak Inbar; Galia Zaide; Yehoshua Broder; Anat Zvi; Theodor Chitlaru; Zeev Altboum; Dana Stein; Sara Cohen; Avigdor Shafferman
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

3.  Oral spore vaccine based on live attenuated nontoxinogenic Bacillus anthracis expressing recombinant mutant protective antigen.

Authors:  R Aloni-Grinstein; O Gat; Z Altboum; B Velan; S Cohen; A Shafferman
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

4.  Use of transposon promoter-probe vectors in the metabolic engineering of the obligate methanotroph Methylomonas sp. strain 16a for enhanced C40 carotenoid synthesis.

Authors:  Pamela L Sharpe; Deana Dicosimo; Melissa D Bosak; Kyle Knoke; Luan Tao; Qiong Cheng; Rick W Ye
Journal:  Appl Environ Microbiol       Date:  2007-01-19       Impact factor: 4.792

5.  Identification of in vivo-expressed immunogenic proteins by serological proteome analysis of the Bacillus anthracis secretome.

Authors:  Theodor Chitlaru; Orit Gat; Haim Grosfeld; Itzhak Inbar; Yael Gozlan; Avigdor Shafferman
Journal:  Infect Immun       Date:  2007-03-12       Impact factor: 3.441

6.  Differential proteomic analysis of the Bacillus anthracis secretome: distinct plasmid and chromosome CO2-dependent cross talk mechanisms modulate extracellular proteolytic activities.

Authors:  Theodor Chitlaru; Orit Gat; Yael Gozlan; Naomi Ariel; Avigdor Shafferman
Journal:  J Bacteriol       Date:  2006-05       Impact factor: 3.490

7.  Dissemination bottleneck in a murine model of inhalational anthrax.

Authors:  Roger D Plaut; Vanessa K Kelly; Gloria M Lee; Scott Stibitz; Tod J Merkel
Journal:  Infect Immun       Date:  2012-07-02       Impact factor: 3.441

8.  Role of anthrax toxins in dissemination, disease progression, and induction of protective adaptive immunity in the mouse aerosol challenge model.

Authors:  Crystal L Loving; Taruna Khurana; Manuel Osorio; Gloria M Lee; Vanessa K Kelly; Scott Stibitz; Tod J Merkel
Journal:  Infect Immun       Date:  2008-10-27       Impact factor: 3.441

9.  Novel and unique diagnostic biomarkers for Bacillus anthracis infection.

Authors:  Sagit Sela-Abramovich; Theodor Chitlaru; Orit Gat; Haim Grosfeld; Ofer Cohen; Avigdor Shafferman
Journal:  Appl Environ Microbiol       Date:  2009-07-31       Impact factor: 4.792

10.  Generation of an artificial double promoter for protein expression in Bacillus subtilis through a promoter trap system.

Authors:  Mingming Yang; Weiwei Zhang; Shengyue Ji; Pinghua Cao; Yulin Chen; Xin Zhao
Journal:  PLoS One       Date:  2013-02-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.